Richard B. Rosen, M.D.
To determine if diode laser with low power will close abnormal vessels, yet preserve normal retina in patients with Wet or exudative form of AMD.
Wet or exudative form of AMD; best-corrected visual acuity of 20/50 to 20/400; age 50 or older.
The updated results confirmed and expanded on the initial results reported in February 2005 that a subgroup of patients, who were enrolled into the study with baseline visual acuity of 20/100 or worse, benefited from TTT treatment. Within the TTT4CNV trial, about 41 percent of the patients enrolled had baseline vision of 20/100 or worse. Specifically, at 12 months following treatment 23 percent of TTT treated eyes in this subgroup improved vision by one or more lines and 14 percent of TTT treated eyes improved vision by three or more lines compared with none of the eyes in the placebo treated control group. Further, at 18 months, there was a two-line benefit in preserving vision in this subgroup when compared to placebo-treated eyes. Specifically, TTT treated eyes on average lost two lines of visual acuity while placebo-treated eyes lost four lines. These findings were statistically significant.
For more information: